Resources | NITAG RESOURCE CENTER

2023 ∙ NACI

Recommendations on the use of conjugate pneumococcal vaccine – 15 valent (PNEU-C-15) and 20 valent (PNEU-C-20) in adults: Economic evidence supplementary appendix

2023 ∙ NACI

Public health level recommendations on the use of pneumococcal vaccines in adults, including the use of 15-valent and 20-valent conjugate vaccines

2023 ∙ NACI

Interim guidance on the use of pneumococcal 15-valent conjugate vaccine (PNEU-C-15) in pediatric populations

2023

NITAG Maturity Assessment Tool (NMAT)

2023 ∙ Commission Technique des Vaccinations

Vaccination strategy against Covid-19: anticipation of vaccination campaigns in 2023

2023 ∙ NACI

Recommendation on Repeated Seasonal Influenza Vaccination

2023 ∙ ATAGI

ATAGI 2023 booster advice

2023 ∙ ATAGI

ATAGI recommendations on use of the Pfizer bivalent (Original/Omicron BA.4/5) COVID-19 vaccine

2023

Updated HPV Technical Dossier on Quadrivalent HPV (Gardasil-4valent) 1-dose Regimen

2023 ∙ Conseil Supérieur de la Santé (CSS)

Pneumococcal vaccination in children and adolescents in Belgium